Relationship Between Serum microRNA-372-3p and Glucose Transporter 4 Levels and Insulin Resistance in Gestational Diabetes Mellitus

Objective:To observe the changes in insulin resistance in patients with gestational diabetes mellitus(GDM)based on the detection of serum microRNA-372-3p and glucose transporter protein 4(GLUT4)levels.Methods:We conducted a retrospective cohort study of 42 patients who were diagnosed with GDM and hospitalized in our hospital during the period from January 2017 to December 2021 and another 42 patients who had normal pregnancy during the same period by collecting their clinical data.We analyzed their serum microRNA expression profiles and miR-372-3p levels to study the relationship between GDM and insulin resistance.Results:The relative expression of miR-372-3p in the serum of patients in the GDM group was significantly higher than that of patients in the control group,but the GLUT 4 level of the GDM group was significantly lower than that of the control group(P<0.05).Compared with the control group,the GDM group had significantly higher levels of fasting blood glucose(FBG),fasting insulin(FINS),2-hour postprandial blood glucose(2h-BG),total cholesterol(TC),triglyceride(TG),and homeostatic model assessment for insulin resistance(HOMA-IR)index but significantly lower homeostasis model assessment ofβ-cell function(HOMA-β)index(P<0.05).The relative expression of miR-372-3p in serum was independently and positively correlated with HOMA-IR,while the level of GLUT4 was independently and negatively correlated with HOMA-IR(P<0.05).Conclusion:Glycosylated hemoglobin test in the early stages of pregnancy(12–13 weeks of gestation)is important to ensure the health of pregnant women and fetuses.The screening and intervention for elevated glucose in pregnant women act as a guideline for the treatment of GDM.Patients with insulin resistance and related complications such as hyperinsulinemia and hypoglycemia should be given priority.

复方丹参滴丸对胰岛素抵抗大鼠的保护作用及其机制研究

目的观察复方丹参滴丸对胰岛素抵抗大鼠糖脂代谢的作用,探讨其改善胰岛素抵抗的机制。方法隔日1次肌肉注射地塞米松1mg/kg诱导SD大鼠产生胰岛素抵抗,并随机分为正常对照组、模型对照组、吡格列酮组、丹参注射针组及复方丹参滴丸浸膏组。给药8周后分别检测空腹血糖、空腹胰岛素、一氧化氮合酶、一氧化氮、胸主动脉肌层/管壁厚度,并采用ELISA法测定脂联素浓度及实时PCR法测定大鼠骨骼肌细胞膜葡萄糖转运蛋白-4 mRNA表达。结果造模成功大鼠胰岛素抵抗指数增加,一氧化氮合酶生成减少,一氧化氮降低,胸主动脉肌层/管壁厚度明显增加,脂联素分泌减少,肌细胞膜葡萄糖转运蛋白-4 mRNA表达降低。而经上述3种药物干预后,大鼠的胰岛素抵抗指数均有不同程度降低,一氧化氮合酶及一氧化氮生成增加,胸主动脉肌层/管壁厚度明显降低,脂联素分泌及肌细胞膜葡萄糖转运蛋白-4 mRNA表达增强(P<0.05或P<0.01),且吡格列酮组及复方丹参滴丸浸膏两组间作用无统计学意义(P>0.05);丹参注射针组作用较弱(P<0.05)。结论复方丹参滴丸通过多靶点调节糖脂代谢而发挥改善胰岛素抵抗的作用,并与其促进脂联素分泌、增强骨骼肌细胞膜葡萄糖转运蛋白-4 mRNA表达密切相关。